Haemophilus influenzae type b conjugate vaccine

S. A. Plotkin, R. S. Daum, G. S. Giebink, C. B. Hall, M. Lepow, E. K. Marcuse, G. H. McCracken, C. F. Phillips, G. B. Scott, H. T. Wright, G. Peter, A. R. Hinman, P. Parkman, R. Gold, J. G. Easton

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


On Dec 22, 1987, the first conjugate vaccine was licensed by the FDA for the prevention of infections due to Haemophilus influenzae type b. This vaccine is a conjugate of H influenzae type b capsular polysaccharide and diphtheria toxoid and is officially designated as Haemophilus b conjugate vaccine (diphtheria toxoid-conjugate). The purpose of this statement is to provide background information, perspective, and recommendations for the use of this product.

Original languageEnglish (US)
Pages (from-to)908-911
Number of pages4
Issue number6
StatePublished - 1988

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Haemophilus influenzae type b conjugate vaccine'. Together they form a unique fingerprint.

Cite this